Skip to main content
Top
Published in: Endocrine Pathology 3/2022

Open Access 03-08-2021 | Endometriosis

Mixed Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) of the Ovary Arising from Endometriosis: Molecular Pathology Analysis in Support of a Pathogenetic Paradigm

Authors: Roberta Maragliano, Laura Libera, Ileana Carnevali, Valeria Pensotti, Giovanna De Vecchi, Margherita Testa, Cristina Amaglio, Eleonora Leoni, Giorgio Formenti, Fausto Sessa, Daniela Furlan, Silvia Uccella

Published in: Endocrine Pathology | Issue 3/2022

Login to get access

Abstract

Primary ovarian neuroendocrine neoplasms (Ov-NENs) are infrequent and mainly represented by well-differentiated forms (neuroendocrine tumors — NETs — or carcinoids). Poorly differentiated neuroendocrine carcinomas (Ov-NECs) are exceedingly rare and only few cases have been reported in the literature. A subset of Ov-NECs are admixed with non-neuroendocrine carcinomas, as it occurs in other female genital organs, as well (mostly endometrium and uterine cervix), and may be assimilated to mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) described in digestive and extra-digestive sites. Here, we present a case of large cell Ov-NEC admixed with an endometrioid carcinoma of the ovary, arising in the context of ovarian endometriosis, associated with a uterine endometrial atypical hyperplasia (EAH). We performed targeted next-generation sequencing analysis, along with a comprehensive immunohistochemical study and FISH analysis for TP53 locus, separately on the four morphologically distinct lesions (Ov-NEC, endometrioid carcinoma, endometriosis, and EAH). The results of our study identified molecular alterations of cancer-related genes (PIK3CA, CTNNB1, TP53, RB1, ARID1A, and p16), which were present with an increasing gradient from preneoplastic lesions to malignant proliferations, both neuroendocrine and non-neuroendocrine components. In conclusion, our findings underscored that the two neoplastic components of this Ov-MiNEN share a substantially identical molecular profile and they progress from a preexisting ovarian endometriotic lesion, in a patient with a coexisting preneoplastic proliferation of the endometrium, genotypically and phenotypically related to the ovarian neoplasm. Moreover, this study supports the inclusion of MiNEN in the spectrum ovarian and, possibly, of all gynecological NENs, among which they are currently not classified.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO Classification of Tumors Editorial Board. Female Genital Tumours. 5th Edition. Lyon: International Agency for Research on Cancer World Health Organisation; 2020. WHO Classification of Tumors Editorial Board. Female Genital Tumours. 5th Edition. Lyon: International Agency for Research on Cancer World Health Organisation; 2020.
2.
go back to reference Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770-1786.CrossRef Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770-1786.CrossRef
3.
go back to reference Uccella S, Mathias-Guiu X, La Rosa S. Genitourinary Neuroendocrine Neoplasms. In: Asa SL, La Rosa S, Mete O, eds. The Spectrum of Neuroendocrine Neoplasia: Springer, Cham; 2021. Uccella S, Mathias-Guiu X, La Rosa S. Genitourinary Neuroendocrine Neoplasms. In: Asa SL, La Rosa S, Mete O, eds. The Spectrum of Neuroendocrine Neoplasia: Springer, Cham; 2021.
4.
go back to reference Eichhorn JH, Young RH, Scully RE. Primary ovarian small cell carcinoma of pulmonary type. A clinicopathologic, immunohistologic, and flow cytometric analysis of 11 cases. Am J Surg Pathol. 1992;16:926–938. Eichhorn JH, Young RH, Scully RE. Primary ovarian small cell carcinoma of pulmonary type. A clinicopathologic, immunohistologic, and flow cytometric analysis of 11 cases. Am J Surg Pathol. 1992;16:926–938.
5.
go back to reference Pini GM, Uccella S, Corinti M, et al. Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior : Description of a case and review of the pertinent literature. Virchows Arch. 2021. Pini GM, Uccella S, Corinti M, et al. Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior : Description of a case and review of the pertinent literature. Virchows Arch. 2021.
6.
go back to reference Uccella S, La Rosa S. Looking into digestive mixed neuroendocrine - nonneuroendocrine neoplasms: subtypes, prognosis, and predictive factors. Histopathology. 2020;77:700-717.CrossRef Uccella S, La Rosa S. Looking into digestive mixed neuroendocrine - nonneuroendocrine neoplasms: subtypes, prognosis, and predictive factors. Histopathology. 2020;77:700-717.CrossRef
7.
go back to reference Bolzacchini E, Digiacomo N, Marrazzo C, et al. BRAF Mutation in Colorectal Rhabdoid and Poorly Differentiated Medullary Carcinomas. Cancers (Basel). 2019;11. Bolzacchini E, Digiacomo N, Marrazzo C, et al. BRAF Mutation in Colorectal Rhabdoid and Poorly Differentiated Medullary Carcinomas. Cancers (Basel). 2019;11.
8.
go back to reference Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol. 2009;40:645-652.CrossRef Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol. 2009;40:645-652.CrossRef
9.
go back to reference Dearth LR, Qian H, Wang T, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis. 2007;28:289-298.CrossRef Dearth LR, Qian H, Wang T, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis. 2007;28:289-298.CrossRef
10.
go back to reference Slovackova J, Grochova D, Navratilova J, et al. Transactivation by temperature-dependent p53 mutants in yeast and human cells. Cell Cycle. 2010;9:2141-2148.CrossRef Slovackova J, Grochova D, Navratilova J, et al. Transactivation by temperature-dependent p53 mutants in yeast and human cells. Cell Cycle. 2010;9:2141-2148.CrossRef
11.
go back to reference Uccella S, La Rosa S, Volante M, et al. Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms. Endocr Pathol. 2018;29:150-168.CrossRef Uccella S, La Rosa S, Volante M, et al. Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms. Endocr Pathol. 2018;29:150-168.CrossRef
12.
go back to reference Wani Y. Interpretation of diffuse Cdx2 expression in endometrioid adenocarcinoma in the absence of morules. Histopathology. 2009;54:495-497.CrossRef Wani Y. Interpretation of diffuse Cdx2 expression in endometrioid adenocarcinoma in the absence of morules. Histopathology. 2009;54:495-497.CrossRef
13.
go back to reference Parra-Herran C, Lerner-Ellis J, Xu B, et al. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. Mod Pathol. 2017;30:1748-1759.CrossRef Parra-Herran C, Lerner-Ellis J, Xu B, et al. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. Mod Pathol. 2017;30:1748-1759.CrossRef
14.
go back to reference Uccella S, La Rosa S, Metovic J, et al. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol. 2021;32:192-210.CrossRef Uccella S, La Rosa S, Metovic J, et al. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol. 2021;32:192-210.CrossRef
15.
go back to reference Howitt BE, Dong F, Vivero M, Shah V, Lindeman N, Schoolmeester JK, Baltay M, MacConaill L, Sholl LM, Nucci MR, McCluggage WG. Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups. Am J Surg Pathol. 2020;44:1541-1548.CrossRef Howitt BE, Dong F, Vivero M, Shah V, Lindeman N, Schoolmeester JK, Baltay M, MacConaill L, Sholl LM, Nucci MR, McCluggage WG. Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups. Am J Surg Pathol. 2020;44:1541-1548.CrossRef
17.
go back to reference Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385-394.CrossRef Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385-394.CrossRef
18.
go back to reference Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med. 2017;376:1835-1848.CrossRef Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med. 2017;376:1835-1848.CrossRef
19.
go back to reference Suda K, Cruz Diaz LA, Yoshihara K, et al. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Cancer Sci. 2020;111:3000-3009.CrossRef Suda K, Cruz Diaz LA, Yoshihara K, et al. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Cancer Sci. 2020;111:3000-3009.CrossRef
20.
go back to reference Suda K, Nakaoka H, Yoshihara K, et al. Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium. Cell Rep. 2018;24:1777-1789.CrossRef Suda K, Nakaoka H, Yoshihara K, et al. Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium. Cell Rep. 2018;24:1777-1789.CrossRef
21.
go back to reference Guo SW. Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology. Hum Reprod Update. 2020;26:423-449.CrossRef Guo SW. Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology. Hum Reprod Update. 2020;26:423-449.CrossRef
22.
go back to reference Bulun SE, Wan Y, Matei D. Epithelial Mutations in Endometriosis: Link to Ovarian Cancer. Endocrinology. 2019;160:626-638.CrossRef Bulun SE, Wan Y, Matei D. Epithelial Mutations in Endometriosis: Link to Ovarian Cancer. Endocrinology. 2019;160:626-638.CrossRef
23.
go back to reference Gaia-Oltean AI, Pop LA, Cojocneanu RM, Buse M, Zimta AA, Kubelac P, Irimie A, Coza OF, Roman H, Berindan-Neagoe I. The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma. Am J Cancer Res. 2021;11:1754-1769.PubMedPubMedCentral Gaia-Oltean AI, Pop LA, Cojocneanu RM, Buse M, Zimta AA, Kubelac P, Irimie A, Coza OF, Roman H, Berindan-Neagoe I. The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma. Am J Cancer Res. 2021;11:1754-1769.PubMedPubMedCentral
Metadata
Title
Mixed Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) of the Ovary Arising from Endometriosis: Molecular Pathology Analysis in Support of a Pathogenetic Paradigm
Authors
Roberta Maragliano
Laura Libera
Ileana Carnevali
Valeria Pensotti
Giovanna De Vecchi
Margherita Testa
Cristina Amaglio
Eleonora Leoni
Giorgio Formenti
Fausto Sessa
Daniela Furlan
Silvia Uccella
Publication date
03-08-2021
Publisher
Springer US
Keyword
Endometriosis
Published in
Endocrine Pathology / Issue 3/2022
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-021-09689-8

Other articles of this Issue 3/2022

Endocrine Pathology 3/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.